BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005; 11(39): 6104-6109 [PMID: 16273634 DOI: 10.3748/wjg.v11.i39.6104] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
2 Jiang C, Cheng G, Liao M, Huang J. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis. World J Surg Oncol 2021;19:81. [PMID: 33741001 DOI: 10.1186/s12957-021-02188-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
4 Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: Percutaneous and open approaches. J Surg Oncol. 2009;100:619-634. [PMID: 20017157 DOI: 10.1002/jso.21364] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 5.7] [Reference Citation Analysis]
5 Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol 2019;25:4614-28. [PMID: 31528090 DOI: 10.3748/wjg.v25.i32.4614] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
6 Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease 2013;45:712-23. [DOI: 10.1016/j.dld.2013.01.012] [Cited by in Crossref: 103] [Cited by in F6Publishing: 113] [Article Influence: 11.4] [Reference Citation Analysis]
7 Huang D, Chen Y, Zeng Q, Zhao J, Wu X, Wu R, Li Y. Blood supply characteristics of pedunculated hepatocellular carcinoma prior to and following transcatheter arterial chemoembolization treatment: An angiographic demonstration. Oncol Lett 2018;15:3383-9. [PMID: 29599845 DOI: 10.3892/ol.2018.7844] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Page AJ, Cosgrove D, Pawlik TM. Comparative effectiveness in hepatic malignancies. Cancer Treat Res 2015;164:195-219. [PMID: 25677025 DOI: 10.1007/978-3-319-12553-4_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, Higurashi T, Goto A, Takahashi H, Abe Y. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol Res. 2009;39:553-562. [PMID: 19527484 DOI: 10.1111/j.1872-034x.2009.00490.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
10 Seinstra BA, van Delden OM, van Erpecum KJ, van Hillegersberg R, Mali WP, van den Bosch MA. Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? Insights Imaging. 2010;1:167-181. [PMID: 23100194 DOI: 10.1007/s13244-010-0027-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
11 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 183] [Article Influence: 15.2] [Reference Citation Analysis]
12 Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011649. [PMID: 28281295 DOI: 10.1002/14651858.cd011649.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
13 Liao M, Huang J, Zhang T, Wu H. Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e68453. [PMID: 23844203 DOI: 10.1371/journal.pone.0068453pone-d-13-13354] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Brown ZJ, Hewitt DB, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34788184 DOI: 10.1080/13543784.2022.2008355] [Reference Citation Analysis]
15 Xie H, Yu H, Tian S, Yang X, Wang X, Yang Z, Wang H, Guo Z. What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis. Oncotarget 2017;8:100508-23. [PMID: 29245997 DOI: 10.18632/oncotarget.20119] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
16 Kim J, Chung DJ, Jung SE, Cho SH, Hahn ST, Lee JM. Therapeutic effect of high-intensity focused ultrasound combined with transarterial chemoembolisation for hepatocellular carcinoma <5 cm: comparison with transarterial chemoembolisation monotherapy--preliminary observations. Br J Radiol 2012;85:e940-6. [PMID: 22553305 DOI: 10.1259/bjr/32750755] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
17 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
18 Yoon I, Yim HJ, Kim JN, Park SM, Kim JH, Lee SH, Chung HH, Lee HS, Lee SW, Choi JH. [A case of advanced hepatocellular carcinoma with portal vein tumor invasion controlled by percutaneous ethanol injection therapy]. Korean J Hepatol 2009;15:90-5. [PMID: 19346790 DOI: 10.3350/kjhep.2009.15.1.90] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Yu D, Meyer T, Patch DW, Burroughs AK. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006;32:594-606. [PMID: 17045407 DOI: 10.1016/j.ctrv.2006.08.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
20 Gu L, Liu H, Fan L, Lv Y, Cui Z, Luo Y, Liu Y, Li G, Li C, Ma J. Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2014;140:199-210. [PMID: 24077865 DOI: 10.1007/s00432-013-1528-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
21 Tsochatzis EA, Fatourou EM, Triantos CK, Burroughs AK. Transarterial therapies for hepatocellular carcinoma. Recent Results Cancer Res 2013;190:195-206. [PMID: 22941022 DOI: 10.1007/978-3-642-16037-0_13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
22 Song DS, Nam SW, Bae SH, Kim JD, Jang JW, Song MJ, Lee SW, Kim HY, Lee YJ, Chun HJ, You YK, Choi JY, Yoon SK. Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2015; 21(8): 2395-2404 [PMID: 25741147 DOI: 10.3748/wjg.v21.i8.2395] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
23 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
24 Mizumoto M, Tokuuye K, Sugahara S, Nakayama H, Fukumitsu N, Ohara K, Abei M, Shoda J, Tohno E, Minami M. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys. 2008;71:462-467. [PMID: 18243571 DOI: 10.1016/j.ijrobp.2007.09.056] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
25 Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0184597. [PMID: 28934265 DOI: 10.1371/journal.pone.0184597] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 8.4] [Reference Citation Analysis]
26 Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, Bain VG, Ma M, Owen R. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev 2012;38:54-62. [PMID: 21726960 DOI: 10.1016/j.ctrv.2011.05.002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
27 Paik EK, Kim MS, Jang WI, Seo YS, Cho CK, Yoo HJ, Han CJ, Park SC, Kim SB, Kim YH. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol. 2016;11:22. [PMID: 26896371 DOI: 10.1186/s13014-016-0597-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
28 Gogia S, Befeler AS. Treating hepatocellular carcinoma without liver transplantation. Curr Gastroenterol Rep 2009;11:69-75. [PMID: 19166662 DOI: 10.1007/s11894-009-0011-9] [Reference Citation Analysis]
29 Zhao J, Zhang H, Wei L, Xie S, Suo Z. Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison. Oncotarget 2017;8:15101-13. [PMID: 27835871 DOI: 10.18632/oncotarget.13145] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
30 Tsochatzis EA, Germani G, Burroughs AK. Transarterial Chemoembolization, Transarterial Chemotherapy, and Intra-arterial Chemotherapy for Hepatocellular Carcinoma Treatment. Seminars in Oncology 2010;37:89-93. [DOI: 10.1053/j.seminoncol.2010.03.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
31 Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010;30:741-749. [PMID: 20331507 DOI: 10.1111/j.1478-3231.2010.02221.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 6.3] [Reference Citation Analysis]
32 Spangenberg HC, Mohr L, Blum HE. [Regional therapy of liver tumors]. Internist (Berl). 2007;48:40-45. [PMID: 17160664 DOI: 10.1007/s00108-006-1771-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Kulik LM, Mulcahy MF, Omary RA, Salem R. Emerging Approaches in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2007;41:839-54. [DOI: 10.1097/mcg.0b013e318060ac52] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
34 Kanhere HA, Leopardi LN, Fischer L, Kitchener MI, Maddern GJ. TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA WITH RADIOLABELLED LIPIODOL. ANZ J Surg 2008;78:371-6. [DOI: 10.1111/j.1445-2197.2008.04480.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
35 Wang S, Zhuang L, Meng Z. Hepatocellular Carcinoma More Than 3 cm in Diameter: A Systematic Review of Transcatheter Arterial Chemoembolization Plus Percutaneous Ethanol Injection versus Transcatheter Arterial Chemoembolization Alone. ISRN Gastroenterol 2013;2013:526024. [PMID: 23936659 DOI: 10.1155/2013/526024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
36 Liu B, Jiang C, Chen S, Huang G, Wang Y, Li J, Xu M, Xie X, Kuang M. Multipronged ethanol ablation combined with TACE for intermediate hepatocellular carcinoma. Minim Invasive Ther Allied Technol 2018;27:300-8. [PMID: 29390939 DOI: 10.1080/13645706.2018.1427598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Choi JI, Kim HB, Kim MJ, Lee JS, Koh YW, An SB, Ko HK, Park JW. Noncontrast chest computed tomography immediately after transarterial chemoembolization in patients with hepatocellular carcinoma: clinical benefits and effect of radiation reduction on image quality in low-dose scanning. Eur J Radiol 2011;80:e188-94. [PMID: 21708441 DOI: 10.1016/j.ejrad.2011.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Tao R, Li X, Ran R, Xiao Z, Zhang H, Kong H, Song Q, Huang Y, Wang L, Huang J. A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. Oncotarget 2017;8:5460-73. [PMID: 27705924 DOI: 10.18632/oncotarget.12348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Wang N, Guan Q, Wang K, Zhu B, Yuan W, Zhao P, Wang X, Zhao Y. TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol. 2011;28:1038-1043. [PMID: 20632218 DOI: 10.1007/s12032-010-9620-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
40 Bhosale P, Szklaruk J, Silverman PM. Current staging of hepatocellular carcinoma: imaging implications. Cancer Imaging. 2006;6:83-94. [PMID: 16829469 DOI: 10.1102/1470-7330.2006.0014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
41 Giovannini M. Le traitement percutané du carcinome hépato-cellulaire. Gastroentérologie Clinique et Biologique 2007;31:347-53. [DOI: 10.1016/s0399-8320(07)89388-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Tanaka M, Ando E, Simose S, Hori M, Kuraoka K, Ohno M, Yutani S, Harada K, Sata M. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. Hepatol Res. 2014;44:194-200. [PMID: 23521520 DOI: 10.1111/hepr.12100] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
43 Liao M, Huang J, Zhang T, Wu H. Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e68453. [PMID: 23844203 DOI: 10.1371/journal.pone.0068453] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
44 Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, Bae SH, Tak WY. Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology 2011;81 Suppl 1:134-40. [PMID: 22212947 DOI: 10.1159/000333276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
45 Huang D, Chen Y, Chen S, Zeng Q, Zhao J, Wu R, Li Y. TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma. Medicine (Baltimore). 2017;96:e7650. [PMID: 28746230 DOI: 10.1097/md.0000000000007650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
46 Salpeter SR, Malter DS, Luo EJ, Lin AY, Stuart B. Systematic Review of Cancer Presentations with a Median Survival of Six Months or Less. Journal of Palliative Medicine 2012;15:175-85. [DOI: 10.1089/jpm.2011.0192] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
47 Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535-1547. [PMID: 16696801 DOI: 10.1111/j.1365-2036.2006.02932.x] [Cited by in Crossref: 250] [Cited by in F6Publishing: 227] [Article Influence: 15.6] [Reference Citation Analysis]
48 Li L, Tian J, Liu P, Wang X, Zhu Z. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: a meta-analysis. Tumori 2016;2016:301-10. [PMID: 27002950 DOI: 10.5301/tj.5000491] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]